On January 14, 2022, Shenyang Xingqi Pharmaceutical Co.,Ltd closed the transaction. The company has issued 5,763,282 shares at a price of CNY 104.5 per share for gross proceeds of CNY 599,669,492.10 in the transaction. The transaction included participation from JPMorgan Chase Bank, National Association for 413,262 shares for CNY 42,999,911.10 , Minsheng Securities Co.,Ltd. for 288,322 shares for CNY 29,999,904.10, Borui Oriental Value No.

12 Private Securities Investment Fund, a fund managed by Xiamen Borui Oriental Investment Management Co., Ltd. for 326,765 shares for CNY 33,999,898.25, UBS Group AG for 355,598 shares for CNY 36,999,971.90, CITIC Securities Company Limited for 1,230,177 shares for CNY 127,999,916.85, CLSA Asset Management Limited for 961,076 shares for CNY 99,999,957.80, Rosefinch Fund Management Co., Ltd. for 576,645 shares for CNY 59,999,912.25, CIB Fund Management Co., Ltd. for 432,484 shares for CNY 44,999,960.20, Nuode Asset Management Co., Ltd. for 740,028 shares for CNY 76,999,913.40, Li Suzhen for 297,933 shares for CNY 30,999,928.65, Ningju Yingshanhong No.4 Private Securities Investment Fund, a fund managed by Ningbo Ningju Asset Management Center (Limited Partnership) for 140,992 shares for CNY 14,670,217.60. The company received net proceeds of CNY 580,179,086.77 in the transaction. The shares issued are subject to restriction period of 6 months from issuance.

The company incurred sponsorship and underwriting fee of CNY 16,791,572.05, legal fee of CNY 1,849,056.60, accounting fee of CNY 754,716.98, and other issuance fee of CNY 95,059.70.